Progesterone Receptor Negative Withdrawn Phase 2 Trials for Cisplatin (DB00515)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03644589Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerTreatment